Lim J, Lasserson T J, Fleetham J, Wright J
Royal Surrey County Hospital, Guildford, Surrey, UK.
Cochrane Database Syst Rev. 2006 Jan 25;2006(1):CD004435. doi: 10.1002/14651858.CD004435.pub3.
Obstructive sleep apnoea-hypopnoea (OSAH) is a syndrome characterised by recurrent episodes of partial or complete upper airway obstruction during sleep that are usually terminated by an arousal. Nasal continuous positive airway pressure (CPAP) is the primary treatment for OSAH , but many patients are unable or unwilling to comply with this treatment. Oral appliances (OA) are an alternative treatment for OSAH.
The objective was to review the effects of OA in the treatment of OSAH in adults.
We searched the Cochrane Airways Group Specialised Register. Searches were current as of June 2005. Reference lists of articles were also searched.
Randomised trials comparing OA with control or other treatments in adults with OSAH .
Two authors independently extracted data and assessed trial quality. Study authors were contacted for missing information.
Sixteen studies (745 participants) met the inclusion criteria. All the studies had some shortcomings, such as small sample size, under-reporting of methods and data, and lack of blinding. OA versus control appliances (six studies): OA reduced daytime sleepiness in two crossover trials (WMD -1.81;95%CI -2.72 to -0.90), and improved apnoea-hypopnoea index (AHI) (-10.78; 95% CI-15.53 to -6.03 parallel group data - five studies). OA versus CPAP (nine studies): OA were less effective than CPAP in reducing apnoea-hypopnoea index (parallel group studies: WMD 13 (95% CI 7.63 to 18.36), two trials; crossover studies: WMD 7.97; (95% CI 6.38 to 9.56, seven trials). However, no significant difference was observed on symptom scores. CPAP was more effective at improving minimum arterial oxygen saturation during sleep compared with OA. In two small crossover studies, participants preferred OA therapy to CPAP. OA versus corrective upper airway surgery (one study): Symptoms of daytime sleepiness were initially lower with surgery, but this difference disappeared at 12 months. AHI did not differ significantly initially, but did so after 12 months in favour of OA.
AUTHORS' CONCLUSIONS: There is increasing evidence suggesting that OA improves subjective sleepiness and sleep disordered breathing compared with a control. CPAP appears to be more effective in improving sleep disordered breathing than OA. The difference in symptomatic response between these two treatments is not significant, although it is not possible to exclude an effect in favour of either therapy. Until there is more definitive evidence on the effectiveness of OA in relation to CPAP, with regard to symptoms and long-term complications, it would appear to be appropriate to recommend OA therapy to patients with mild symptomatic OSAH, and those patients who are unwilling or unable to tolerate CPAP therapy. Future research should recruit patients with more severe symptoms of sleepiness, to establish whether the response to therapy differs between subgroups in terms of quality of life, symptoms and persistence with usage. Long-term data on cardiovascular health are required.
阻塞性睡眠呼吸暂停低通气综合征(OSAH)是一种以睡眠期间反复出现部分或完全上气道阻塞发作且通常由觉醒终止为特征的综合征。鼻持续气道正压通气(CPAP)是OSAH的主要治疗方法,但许多患者无法或不愿依从这种治疗。口腔矫治器(OA)是OSAH的一种替代治疗方法。
本研究旨在综述OA治疗成人OSAH的效果。
我们检索了Cochrane气道组专业注册库。检索截至2005年6月。同时也检索了文章的参考文献列表。
比较OA与对照或其他治疗方法治疗成人OSAH的随机试验。
两位作者独立提取数据并评估试验质量。联系研究作者获取缺失信息。
16项研究(745名参与者)符合纳入标准。所有研究都存在一些缺陷,如样本量小、方法和数据报告不充分以及缺乏盲法。OA与对照矫治器(6项研究):在两项交叉试验中,OA降低了日间嗜睡程度(加权均数差 -1.81;95%可信区间 -2.72至 -0.90),并改善了呼吸暂停低通气指数(AHI)(-10.78;95%可信区间 -15.53至 -6.03,平行组数据 - 5项研究)。OA与CPAP(9项研究):在降低呼吸暂停低通气指数方面,OA不如CPAP有效(平行组研究:加权均数差13(95%可信区间7.63至18.36),2项试验;交叉研究:加权均数差7.97;(95%可信区间6.38至9.56,7项试验)。然而,在症状评分方面未观察到显著差异。与OA相比,CPAP在改善睡眠期间最低动脉血氧饱和度方面更有效。在两项小型交叉研究中,参与者更喜欢OA治疗而非CPAP。OA与上气道矫正手术(1项研究):手术最初使日间嗜睡症状较轻,但这种差异在12个月时消失。最初AHI无显著差异,但在第12个月时有利于OA。
越来越多的证据表明,与对照相比,OA可改善主观嗜睡和睡眠呼吸紊乱。CPAP在改善睡眠呼吸紊乱方面似乎比OA更有效。这两种治疗方法在症状反应上的差异不显著,尽管无法排除对任何一种治疗方法有利的效果。在有关于OA相对于CPAP在症状和长期并发症方面有效性的更确切证据之前,对于轻度症状性OSAH患者以及那些不愿或无法耐受CPAP治疗的患者,推荐OA治疗似乎是合适的。未来的研究应招募嗜睡症状更严重的患者,以确定不同亚组在生活质量、症状和治疗依从性方面对治疗的反应是否不同。需要关于心血管健康的长期数据。